NCT05108805 2025-03-27
Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting
Vanderbilt-Ingram Cancer Center
Phase 4 Completed
Clinical Trials
6 trialsNCT02926586 2024-10-01
Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 4 Completed
NCT00361140 2017-03-03
Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)
H. Lee Moffitt Cancer Center and Research Institute
Phase 4 Completed
NCT02784561 2016-05-27
Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Chinese PLA General Hospital
Phase 4 Unknown
NCT02024308 2013-12-31
AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy
Changhai Hospital
Phase 4 Unknown
NCT01124526 2010-05-17
Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma
Asociacion Espanola de Hematologia y Hemoterapia
Phase 4 Completed